NYSE:CRLLife Sciences
Charles River Laboratories (CRL) Q1 Loss Of US$14.8m Tests Profitability Recovery Narrative
Charles River Laboratories International (CRL) opened 2026 with Q1 revenue of US$995.8 million and a basic EPS loss of US$0.30, alongside net income excluding extra items of a US$14.8 million loss, with the stock trading around US$181.68. The company has seen quarterly revenue move from US$984.2 million in Q1 2025 to just over US$1.0 billion across several recent periods, while basic EPS has swung between a profit of about US$1.11 and a much larger loss of about US$5.62. This has left margins...